# Polyp Biopsy Market

> Polyp Biopsy Market Research Report Information by Type (Colonoscopy, Colposcopy-Directed Biopsy, Esophagogastroduodenoscopy and Laryngoscopy), Distribution Channel (Online Sales Channels, Retail Pharmacies), End User (Hospitals & Clinics, Diagnostic Centres and Academic & Research Organizations) - Forecast till 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.47%
- **2024:** $ 1.83 Million
- **2025:** $ 1.95 Million
- **2035:** $ 3.3 Million
- **Key Players:** Companies such as Medtronic (US), Boston Scientific (US), Olympus Corporation (JP), Cook Medical (US), Conmed Corporation (US), Fujifilm Holdings Corporation (JP), Hologic (US), Stryker Corporation (US), Ethicon (US) are some of the major participants in the market.

**Report ID:** MRFR/MED/1141-HCR · **Pages:** 90 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** July 22, 2026

**URL:** https://www.marketresearchfuture.com/reports/polyp-biopsy-market-1673

---

## Market Summary

## **Polyp Biopsy Market Overview**

The Polyp biopsy market is expected to reach USD 2.8 Billion by 2032 at 8.3% CAGR during the forecast period 2023-2032. Polyps are benign growths generated by aberrant cell division. They can, however, become malignant if left untreated. To summarise, it is critical to detect polyps to avert cancer. The biopsy is a common diagnostic procedure for this purpose. A sample of tissue from the polyp is extracted and studied under a microscope in this operation.

With the use of a polyp biopsy, diseases such as non-small cell lung carcinoma, head and neck cancer, breast cancer, lymphomas, leukemia, and breast and liver cancer can be detected early. These are the five most frequent cancers that affect people all around the world. Cancers of the bowel, stomach, and liver are also common worldwide. As a result of the increased incidence of various tumors, the Polyp Biopsy Market Growth has grown.

Because of the adoption of western lifestyles and choices in economically developing countries, such as smoking, bad food, physical inactivity, and fewer childbirths, the future load is predicted to be considerably greater. The demand for early cancer diagnosis is expected to have an impact on the polyp biopsy market growth. In the diagnosis of solid and various cancers, polyp biopsy has been in high demand which has changed the polyp biopsy market outlook. According to WHO statistics, cancer is the world's second-biggest cause of death, with around 18 million new cases reported globally during the historic forecast period.

In the next two decades, the number of new cases is predicted to increase by almost 70%. The global burden of cancer is anticipated to increase to 21.7 million new cases and 13 million cancer deaths by 2030, owing to population aging.

**COVID Analysis**

Since its first appearance in Wuhan, China, in December 2019, the coronavirus disease, caused by the novel severe acute respiratory syndrome coronavirus, has swiftly spread over the world, prompting the World Health Organization to designate it a pandemic. The rising number of patients requiring hospitalization necessitated the temporary conversion of entire hospitals into COVID-19 facilities and a significant redeployment of medical professionals to address the pandemic's continuous load. All elective operations should be canceled or postponed until the epidemiologic situation improves, to more effectively combat the pandemic and free up hospital resources.

This postponement of elective surgery and invasive diagnostic treatments will have a significant impact on patient quality of life, since some patients will present with more advanced disease, necessitating more difficult surgeries and poor surgical results. As a result, diagnostic and surgical procedures had to be altered to provide the bare minimum of care for non-urgent and non-oncologic patients, primarily through the use of personal protective equipment (PPE) and various physical barriers to reduce exposure to potentially viral-containing droplets and aerosol particles in the operating room.

Some reports showed a new technique for removing cancer i.e. polyp biopsy in the office setting while also taking into account the safety precautions advised for ambulatory examinations.

**Polyp Biopsy Market Dynamics**

**Drivers**

The polyp biopsy market share is expected to develop due to rising polyp occurrences, aging demographics, and the rising frequency of colorectal cancer. Furthermore, technical improvements in the field of biopsy are projected to propel the market. The market can be ascribed to the rising demand for Polyp Biopsy in Hospitals, Clinics, Diagnostic Centers, and Research Laboratories applications all over the world. Within the diagnostic sector, these diagnostics are gaining traction. The market is predicted to increase rapidly, with rising breast cancer occurrences being one of the main drivers during the market forecast.

**Restraints**

Regulatory uncertainty and the risk of infection after biopsy are projected to limit market growth throughout the projection period. The most significant market constraint is the high cost of medications, as biopsy is far more expensive and the typical person cannot afford it. The market value of polyp biopsies is likely to be hampered by the FDA's strict approval standards for new treatments or medications, as well as a rise in demand for alternative treatment methods. Lack of awareness, particularly in developing nations, is projected to be a barrier for the polyp biopsy market outlook over the forecast period.

Biopsy-related technology breakthroughs are projected to drive market. Technological advancements and developments will give profitable opportunities for Global market participants during the forecast years. Polyp biopsies are growing more popular throughout the world's population. Healthcare capital expenditure installed base of various types of products for the polyp biopsy market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the polyp biopsy market are all increasing as a result of technological advancements during the forecast period.

## **Polyp Biopsy Market Segment Overview**

### **Based on the type, the global market has been segmented as follows:**

### **Based on the distribution channel, the global market has been segmented as follows:**

### **Based on the end-user, the global market has been segmented as follows:**

### **Polyp Biopsy Market Regional Classification**

Due to well-developed healthcare infrastructure and an increase in the creation of polyps in individuals, the Americas are expected to lead the polyp biopsy market.

The second-largest share of the market is predicted to be held by Europe. This can be ascribed to the region's robust healthcare sector and government backing.

China, Japan, India, Australia, South Korea, and the rest of Asia-Pacific make up the polyp biopsy market in Asia-Pacific. Because of the high frequency of polyps, rising healthcare expenditures, and increased market penetration, the area is expected to have the greatest CAGR during the forecast period. During the historic forecast period, the prevalence of polyps in mainland China was predicted to be around 23.9 percent.

Due to underdeveloped economies, severe government controls, and low per capita income in Africa, the Middle East, and Africa are expected to hold the smallest part of the market. Because of its strong healthcare infrastructure and the existence of economies like Saudi Arabia, Kuwait, and Dubai, the Middle East is expected to lead the industry.

### **Polyp Biopsy Market Competitive Landscape**

Significant events, such as business combinations, joint ventures, achievements, new product innovations, or market activities, are organized by the leading key players to expand the market growth. The major players provide information such as company snapshots, financial position, recent developments, and other pertinent information. This helps the company flourish and this important personnel realize their objectives. The major key players of the global polyp biopsy market are as follows:

- Cardinal Health, Inc.
- [**Angiotech**](https://www.argonmedical.com/product/pro-mag-ultra-automatic-biopsy-instrument/)
- Carefusion Corporation
- R. Bard, Inc.
- Hologic, Inc.
- INRAD Inc.
- NeoDynamics AB
- Devicor Medical Products Inc.
- Olympus
- IZI Medical Products
- DTR Medica

**Recent Developments**

IZI Medical Products, LLC, a major developer of medical devices used in interventional radiology and interventional oncology treatments, has launched the Quick-Core Auto Biopsy Systems for polyp biopsy. The Quick-Core Auto is a portable, fully automatic biopsy devices that enhances the dependability, precision, and quality of IZI's semi-automatic Quick-Core biopsy system.

NeoDynamics AB, a MedTech company focused to improve breast cancer diagnosis and treatment, has announced a collaboration with the Buckinghamshire Healthcare NHS Trust in London for their NeoNavia pulse biopsy device.

**Polyp Biopsy Market Report Overview**

The Polyp Biopsy Market detailed study will examine data changes and their impact on the market at a global level. It also examines the market's general growth and companies' ability to manage and maintain profit levels, which is critical for any investor looking to start or expand a business in the same sector. This report is broken down into numerous sections that address distinct aspects of the market. The Market's growth factors, drivers, restraints, and trends have all been studied using research approaches.

The research identifies the region and market category that is likely to expand the fastest and dominate the industry.

**Intended Audience**

## Market Drivers

### Market Growth Projections

The Global Polyp Biopsy Market Industry is poised for substantial growth, with projections indicating a market value of 1.58 USD Billion in 2024 and an anticipated increase to 3.56 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 7.68% from 2025 to 2035, highlighting the increasing demand for polyp biopsy procedures driven by various factors such as rising colorectal cancer incidence, advancements in biopsy techniques, and government initiatives promoting screening.

- According to IHME, the growing global burden of digestive diseases and colorectal cancer continues increasing demand for advanced diagnostic procedures and early biopsy-based disease detection.

### Growing Geriatric Population

The aging population worldwide is a crucial factor propelling the Global Polyp Biopsy Market Industry. Older adults are at a higher risk for developing colorectal polyps and cancer, leading to an increased need for screening and biopsy procedures.
As the global demographic shifts towards an older population, healthcare systems are likely to see a surge in demand for polyp biopsies. This trend is expected to be reflected in market growth, with projections indicating a rise to 3.56 USD Billion by 2035. The correlation between age and cancer incidence underscores the importance of addressing this demographic shift in the context of market expansion.

- According to the World Bank, increasing global life expectancy and a rapidly expanding elderly population continue raising demand for colorectal screening and early cancer detection services.

### Advancements in Biopsy Techniques

Technological innovations in biopsy techniques are significantly influencing the Global Polyp Biopsy Market Industry. Enhanced imaging technologies, such as high-definition [endoscopy](https://www.marketresearchfuture.com/reports/endoscopy-devices-market-1967)and virtual colonoscopy, improve the accuracy of polyp detection and characterization. These advancements not only facilitate earlier diagnosis but also increase the efficiency of biopsy procedures. As healthcare providers adopt these cutting-edge technologies, the demand for polyp biopsies is likely to surge. This shift towards more sophisticated diagnostic methods aligns with the industry's growth trajectory, as evidenced by the anticipated market expansion to 3.56 USD Billion by 2035.

- According to PubMed, high-definition endoscopy, image-enhanced visualization, and advanced biopsy technologies have significantly improved colorectal polyp detection rates and diagnostic accuracy.

### Increased Awareness and Education

Heightened awareness and education regarding colorectal health are driving factors in the Global Polyp Biopsy Market Industry. Campaigns aimed at educating the public about the risks of colorectal cancer and the importance of early detection have led to increased screening rates. As individuals become more informed about the benefits of polyp biopsies, they are more likely to seek these procedures. This growing awareness is anticipated to contribute to the market's expansion, with estimates suggesting a market value of 1.58 USD Billion in 2024, potentially reaching 3.56 USD Billion by 2035.

- According to PubMed, public awareness campaigns and physician-led screening initiatives have increased participation in colorectal cancer screening, supporting earlier diagnosis and improved patient outcomes.

###  

### Rising Incidence of Colorectal Cancer

The increasing prevalence of colorectal cancer globally is a primary driver for the Global Polyp Biopsy Market Industry. As awareness of the disease rises, more individuals undergo screening procedures, leading to a higher demand for polyp biopsies. According to health statistics, colorectal cancer remains one of the leading causes of cancer-related deaths worldwide. This trend is expected to contribute to the market's growth, with projections indicating that the market will reach 1.58 USD Billion in 2024 and potentially expand to 3.56 USD Billion by 2035, reflecting a compound annual growth rate of 7.68% from 2025 to 2035.

- According to IHME, colorectal cancer remains among the leading causes of cancer burden globally, reinforcing the need for widespread screening and biopsy-based diagnosis.

### Government Initiatives and Screening Programs

Government initiatives aimed at promoting cancer screening are pivotal in shaping the Global Polyp Biopsy Market Industry. Many countries have implemented national screening programs that encourage early detection of colorectal cancer. These programs often include recommendations for regular colonoscopies, which inherently involve polyp biopsies. As a result, the number of individuals undergoing these procedures is expected to rise, thereby driving market growth. The proactive stance taken by health authorities not only raises awareness but also enhances accessibility to screening services, contributing to the projected market value of 1.58 USD Billion in 2024.

- According to PubMed, organized colorectal cancer screening programs have demonstrated improved early detection rates and increased identification of precancerous polyps through routine colonoscopy.

## Future Outlook

The Polyp Biopsy Industry size is projected to reach USD 3.3 Billion by 2035, growing at a CAGR of 5.47%, driven by technological advancements, increasing prevalence of colorectal cancer, and rising awareness of early detection.

**New opportunities:**

- Development of AI-driven diagnostic tools for enhanced accuracy Expansion of telehealth services for remote biopsy consultations Investment in minimally invasive biopsy technologies to reduce patient recovery time

By 2035, the Polyp Biopsy Market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Colonoscopy (Largest) vs. Endoscopy (Fastest-Growing)

In the Polyp Biopsy Market, colonoscopy currently represents the largest application segment, capturing a significant 59% portion of the overall market share. This method is widely accepted as the gold standard for polyp detection and removal, driving its dominant position. In contrast, endoscopy is emerging as a rapidly growing segment, fueled by advancements in technology and increased awareness among healthcare providers and patients alike regarding its effectiveness and safety in diagnosing conditions.

Medtronic (US) continues advancing colonoscopy technologies through innovative visualization systems and precision biopsy instruments that improve colorectal polyp detection and clinical efficiency.

### By Type of Polyp: Adenomatous Polyp (Largest) vs. Hyperplastic Polyp (Fastest-Growing)

In the Polyp Biopsy Market, the distribution of market share among the various types of polyps reveals that the Adenomatous Polyp segment holds the largest 56% share. This can be attributed to its association with increased cancer risk, prompting regular screening and biopsy procedures. Following closely is the Hyperplastic Polyp segment, which, while not as common in terms of market share, is experiencing rapid growth. As healthcare providers enhance awareness and screening protocols, the uptake of biopsies for hyperplastic polyps is expected to rise significantly.

Boston Scientific (US) continues strengthening gastrointestinal intervention technologies supporting effective identification and removal of adenomatous polyps during colorectal screening procedures.

### By Method of Biopsy: Endoscopic Biopsy (Largest) vs. Surgical Biopsy (Fastest-Growing)

In the Polyp Biopsy Market, the Endoscopic Biopsy segment has established itself as the largest method, capturing significant 67% market share due to its minimally invasive nature and precise tissue sampling capabilities. Following this, the Surgical Biopsy segment is gaining traction, with an increasing number of clinical applications favoring its thoroughness and accuracy in challenging cases. As such, these methods represent critical aspects of polyp evaluation and management in clinical practice.

Endoscopic Biopsy (Dominant) vs. Surgical Biopsy (Emerging)

Endoscopic Biopsy stands as the dominant method in the Polyp Biopsy Market, offering a less invasive option that allows for real-time visualization during procedures. This method is recognized for its ease of use and safety profile, making it the preferred choice among healthcare professionals. On the other hand, Surgical Biopsy is emerging as a significant alternative, particularly in complex cases where more extensive tissue sampling is necessary. This growing method is fueled by advances in surgical techniques and improved recovery outcomes, solidifying its position as a competitive option in the polyp biopsy landscape.

### By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Polyp Biopsy Market, hospitals represent the largest segment, accounting for a significant 63% share due to their extensive resources and ability to perform a wide range of diagnostic procedures. This dominance is driven by the increasing prevalence of colorectal cancer and the high volume of patient referrals for polyp biopsies. Diagnostic laboratories, being specialized facilities, are witnessing rapid growth, attributed to advancements in biopsy technologies and the rising demand for accurate and timely pathology results.

Hospitals: Dominant vs. Diagnostic Laboratories: Emerging

Hospitals serve as the cornerstone of the Polyp Biopsy Market, providing crucial services with advanced imaging technologies and expert pathologists. Their established infrastructure facilitates a high patient throughput, allowing for comprehensive biopsy services. On the other hand, diagnostic laboratories have emerged as pivotal players, driven by increased collaboration with hospitals and outpatient clinics. They leverage innovative techniques and automation to enhance diagnostic accuracy and reduce turnaround times, positioning themselves as vital contributors to the market, particularly in urban areas where access to specialized services is paramount.

## Regional Market Share Analysis

### North America : Market Leader in Biopsy Technology

North America leads in the Polyp Biopsy Market Size, accounting for over 49.18% of the global revenue in 2024. The region's growth is driven by increasing incidences of colorectal cancer, advancements in biopsy technologies, and supportive healthcare policies. Regulatory bodies are emphasizing early detection and preventive measures, further boosting demand for polyp biopsy procedures.

- According to the CDC, colorectal cancer remains one of the leading causes of cancer-related deaths in the United States, supporting continued investment in screening programs, colonoscopy services, and advanced biopsy technologies for early diagnosis.

The competitive landscape in North America is robust, featuring key players such as Medtronic, Boston Scientific, and Hologic. The U.S. is the leading country, supported by a well-established healthcare infrastructure and high healthcare expenditure. The presence of major manufacturers and continuous innovation in biopsy devices are critical factors contributing to the region's market strength.

- GE HealthCare invests approximately USD 1 billion annually in research and development, supporting continuous innovation in diagnostic imaging, endoscopy-support technologies, and precision healthcare infrastructure that strengthens gastrointestinal disease diagnosis.

### Europe : Emerging Market with Growth Potential

Europe Polyp Biopsy Market was valued at USD 0.5 Billion in 2024, making it the second-largest regional market with a 27.32% share. The region's growth is fueled by rising awareness of colorectal cancer screening and favorable reimbursement policies. Regulatory frameworks are increasingly supportive of innovative biopsy technologies, which enhances patient access to advanced diagnostic tools.

- The European Medicines Agency (EMA) coordinates medicine evaluation across 27 EU Member States, supporting regulatory advancement of innovative gastrointestinal diagnostics and improving patient access to advanced biopsy technologies across Europe.

The emphasis on preventive healthcare is a significant driver for market expansion in this region. Leading countries in Europe include Germany, France, and the UK, where healthcare systems are investing in advanced medical technologies. The competitive landscape features key players like Olympus Corporation and Fujifilm Holdings. The presence of established manufacturers and ongoing research initiatives are pivotal in shaping the market dynamics in Europe.

### Asia-Pacific : Rapidly Growing Healthcare Sector

The Asia-Pacific region is emerging as a significant player in the Polyp Biopsy Market, with a market size of 0.3 in 2025. The growth is driven by increasing healthcare investments, rising awareness of colorectal cancer, and improving healthcare infrastructure. Regulatory bodies are focusing on enhancing diagnostic capabilities, which is expected to further stimulate demand for polyp biopsy procedures across the region.

Countries like Japan, China, and India are leading the market, supported by a growing population and increasing healthcare expenditure. The competitive landscape includes key players such as Cook Medical and Conmed Corporation. The region's market is characterized by a mix of established companies and new entrants, fostering innovation and competition in biopsy technologies.

### Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Polyp Biopsy Market, with a market size of 0.11 in 2025. The growth is primarily driven by increasing awareness of colorectal cancer and the need for improved diagnostic tools. However, challenges such as limited healthcare infrastructure and varying regulatory environments can hinder market expansion.

Efforts are being made to enhance healthcare access and improve patient outcomes in this region. Leading countries include South Africa and the UAE, where healthcare investments are on the rise. The competitive landscape is still developing, with a few key players like Ethicon and Stryker Corporation making their mark. The region's potential for growth is significant, but it requires concerted efforts to overcome existing challenges and enhance healthcare delivery.

## Competitive Benchmarking

The Polyp Biopsy Market is characterized by a dynamic competitive landscape, driven by advancements in technology, increasing prevalence of colorectal cancer, and a growing emphasis on early detection. Key players such as Medtronic (US), Boston Scientific (US), and Olympus Corporation (JP) are at the forefront, each adopting distinct strategies to enhance their market presence. Medtronic (US) focuses on innovation through the development of minimally invasive biopsy tools, while Boston Scientific (US) emphasizes strategic partnerships to expand its product offerings. Olympus Corporation (JP) is leveraging its expertise in imaging technologies to enhance diagnostic accuracy, thereby shaping a competitive environment that prioritizes technological advancement and patient outcomes.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and optimize supply chains. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies like Hologic (US) and Stryker Corporation (US) is notable, as they drive innovation and set industry standards, thereby influencing smaller competitors and shaping market dynamics.
In November Medtronic (US) announced the launch of a new line of advanced polyp biopsy devices designed to improve diagnostic precision. This strategic move is significant as it aligns with the growing demand for minimally invasive procedures, potentially enhancing patient outcomes and expanding Medtronic's market share. The introduction of these devices may also stimulate competition, prompting other companies to innovate further.
In October Boston Scientific (US) entered into a collaboration with a leading research institution to develop next-generation biopsy technologies. This partnership is strategically important as it not only enhances Boston Scientific's R&D capabilities but also positions the company to leverage cutting-edge research in its product development, thereby maintaining a competitive edge in the market.
In September Olympus Corporation (JP) unveiled a new imaging system that integrates AI capabilities for real-time analysis during polyp biopsies. This innovation is likely to redefine diagnostic processes, offering enhanced accuracy and efficiency. By incorporating AI, Olympus is not only improving its product offerings but also setting a new standard for the industry, which may compel competitors to adopt similar technologies.
As of December the Polyp Biopsy Market is witnessing trends such as digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition underscores the importance of developing cutting-edge solutions that meet the evolving needs of healthcare providers and patients alike.

## Recent News & Developments

IZI Medical Products, LLC, a major developer of medical devices used in interventional radiology and interventional oncology treatments, has launched the Quick-Core Auto Biopsy Systems for polyp biopsy. The Quick-Core Auto is a portable, fully automatic biopsy devices that enhances the dependability, precision, and quality of IZI's semi-automatic Quick-Core biopsy system.

NeoDynamics AB, a MedTech company focused to improve breast [cancer diagnosis](https://www.marketresearchfuture.com/reports/cancer-diagnostics-market-1962) and treatment, has announced a collaboration with the Buckinghamshire Healthcare NHS Trust in London for their NeoNavia pulse biopsy device.

## Report Scope

| MARKET SIZE 2024 | 1.83(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1.95(USD Million) |
| MARKET SIZE 2035 | 3.3(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.47% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Medtronic (US), Boston Scientific (US), Olympus Corporation (JP), Cook Medical (US), Conmed Corporation (US), Fujifilm Holdings Corporation (JP), Hologic (US), Stryker Corporation (US), Ethicon (US) |
| Segments Covered | Application, Type of Polyp, Technique, End User |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance diagnostic accuracy in the Polyp Biopsy Market. |
| Key Market Dynamics | Technological advancements in diagnostic tools drive growth and enhance accuracy in the polyp biopsy market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Polyp Biopsy Market by 2035?**
A: The Polyp Biopsy Market is projected to reach a valuation of 3.3 USD Million by 2035.

**Q: What was the market valuation of the Polyp Biopsy Market in 2024?**
A: In 2024, the Polyp Biopsy Market was valued at 1.83 USD Million.

**Q: What is the expected CAGR for the Polyp Biopsy Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Polyp Biopsy Market during the forecast period 2025 - 2035 is 5.47%.

**Q: Which companies are considered key players in the Polyp Biopsy Market?**
A: Key players in the Polyp Biopsy Market include Medtronic, Boston Scientific, Johnson & Johnson, and Olympus Corporation.

**Q: What are the primary applications of polyp biopsy procedures?**
A: The primary applications of polyp biopsy procedures include colonoscopy, endoscopy, surgical procedures, and diagnostic testing.

**Q: How do adenomatous polyps compare to hyperplastic polyps in market valuation?**
A: Adenomatous polyps are projected to generate a market valuation of 1.32 USD Million, while hyperplastic polyps are expected to reach 0.99 USD Million.

**Q: What methods of biopsy are utilized in the Polyp Biopsy Market?**
A: The methods of biopsy utilized in the Polyp Biopsy Market include endoscopic biopsy, surgical biopsy, forceps biopsy, and snare biopsy.

**Q: Which end users are driving the demand in the Polyp Biopsy Market?**
A: The demand in the Polyp Biopsy Market is driven by hospitals, diagnostic laboratories, outpatient clinics, and research institutions.

**Q: What is the market valuation for endoscopic biopsy in 2024?**
A: In 2024, the market valuation for endoscopic biopsy was 0.73 USD Million.

**Q: How does the market for surgical procedures in polyp biopsy compare to other applications?**
A: The market for surgical procedures in polyp biopsy was valued at 0.35 USD Million in 2024, indicating a smaller share compared to colonoscopy and endoscopy.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/polyp-biopsy-market-1673*